References
- Nietlispach F, Webb JG, Ye J, et al. Pathology of transcatheter valve therapy. JACC. 2012;5(5):582–590. doi:10.1016/j.jcin.2012.03.012.
- Ternacle J, Krapf L, Mohty D, et al. Aortic stenosis and cardiac amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2019;74(21):2638–2651. doi:10.1016/j.jacc.2019.09.056.
- Scully PR, Treibel TA, Fontana M, et al. Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;71(4):463–464. doi:10.1016/j.jacc.2017.11.037.
- Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879–2887. doi:10.1093/eurheartj/ehx350.
- Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41(29):2759–2767. doi:10.1093/eurheartj/ehaa170.